AstraZeneca
Karolina Andersson Sundell, PhD, is the Evidence Strategy Lead within the Cardiovascular, Metabolic and Renal disease area at AstraZeneca based in Gothenburg, Sweden. She has worked in different roles in evidence generation at AstraZeneca since she joined the company in 2015 as an epidemiologist. Since 2019 Karolina has held leadership roles leading epidemiologists and evidence strategy work within the field of Cardiovascular and Metabolic diseases.
Prior to joining AstraZeneca, Karolina was a senior lecturer and Associate Professor in Public Health and Pharmaceutical Outcomes Research at University of Gothenburg and before that in the Nordic School of Public Health. There she was doing and leading research as well as teaching and leading courses for undergraduates as well as postgraduate students in epidemiology, pharmacoepidemiology, research methods in public health and Pharmaceutical outcomes research. After joining AstraZeneca she remained an adjunct senior lecturer at University of Gothenburg for four years focusing on supervision and research in pharmacoepidemiology with focus on medication adherence and pharmaceutical policy. After finishing her PhD Karolina served at the Nordic School of Public Health as a post doc researcher which gave opportunity to work with data from other Nordic countries beyond Sweden and different types of data collection and data sources. She wrote her dissertation on the Swedish Pharmaceutical Benefit Reforms.
She has more than 40 original research publications to her credit in international peer-review journals as well as eight reviews and commentaries and one book chapter. Her area of expertise includes pharmacoepidemiology with long experience in both drug utilization studies and studies assessing effects of medicines using secondary data from registers and databases as well as primary data collection. in addition, another area of focus has been on changes in pharmaceutical and health care policy changes targeting medications and the access to medications.